| Date | Title | Description |
| 24.01.2026 | Swiss VC Powerhouse Vi Partners Secures New Fund, Marks 25 Years of Innovation | Swiss venture capital titan Vi Partners celebrates 25 years of market leadership. It announced a significant first close for its new CHF 150 million (approximately €161M) fund. This strategic investment vehicle targets early-stage technolog... |
| 22.01.2026 | Vi Partners marks 25 years with first close of €161M new venture fund | Vi Partners this week announced the first close of its latest venture capital fund, targeting €161 million (CHF 150 million). It coincides with Vi Partners' 25th anniversary, marking a quarter-century of continuous venture capital activity.... |
| 25.09.2020 | Recognition for Swiss innovation | |
| 25.09.2020 | Recognition for Swiss innovation | The first accolades were bestowed onto two personalities for their achievements.
Women in Database Research Award
Anastasia Ailamaki, Professor at EPFL’s School of Computer and Communication Sciences (IC) and CEO & Co-Founder at RAW Lab... |
| 03.08.2020 | Female entrepreneurs in the spotlight | As part of its ambition to achieve gender parity, the European Commission launched the EU Prize for Women Innovators, funded by EU’s Horizon 2020 programme for research and innovation. The program aims to create awareness of the need for mo... |
| 03.08.2020 | Female entrepreneurs in the spotlight | |
| 16.07.2019 | Boehringer Ingelheim to acquire Swiss cancer vaccine developer for up to 325M euros | Amal’s lead product candidate is ATP128, a therapeutic cancer vaccine that has been in preclinical development and is expected to start first-in-human clinical trials in Stage IV colorectal cancer later this month. The company describes its... |
| 16.07.2019 | Amal Therapeutics becomes a subsidiary of a German Pharma giant | |
| 03.05.2019 | AMAL Therapeutics enters clinical collaboration with Boehringer Ingelheim | |
| 12.11.2018 | AMAL Therapeutics raises over CHF 33 million! | AMAL Therapeutics raises over CHF 33 million! 12.11.2018 10:35, Charlotte Pichon linkedIn facebook twitter instagram youtube -->
The Geneva-based startup just announced a massive news on Monday morning. It completed the second closing of... |
| 12.11.2018 | AMAL Therapeutics raises over CHF 33 million! | What is AMAL Therapeutics and how did you first get started working on therapeutic vaccines?
AMAL Therapeutics is a Swiss biotech company developing therapeutic vaccines with a focus on oncology. Our goal: bring a novel approach to fight ca... |
| 12.11.2018 | Amal Therapeutics Closes €29M in Series B Funding | Amal Therapeutics, a Geneva, Switzerland-based biotech developing peptide-based therapeutic cancer vaccines, completed the second closing of its €29M Series B financing round.
The round was co-led by Boehringer Ingelheim Venture Fund, with ... |
| 12.11.2018 | AMAL Therapeutics finalises CHF 33 million Series B round | |
| 19.06.2018 | Un premier IPO Day lausannois couronné de succès | |
| 18.05.2018 | First IPO Day in Lausanne on the horizon | |
| 10.11.2017 | "An IPO has become a serious alternative” | |
| 06.09.2017 | Amal Therapeutics Raises €8M in First Closing of Series B Funding Round | Amal Therapeutics, a Geneva, Switzerland-based biotech startup developing novel, peptide-based therapeutic cancer vaccines, raised €8M in first closing of Series B funding round.
The round was co-led by Boehringer Ingelheim Venture Fund, Bi... |
| 05.09.2017 | AMAL Therapeutics Raises €8 Million (CHF 8.8 Million) in First Closing of Series B Financing Round | Financing round co-led by Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund |
| 05.09.2017 | Cancer vax biotech Amal grabs $10M round; Global Blood Therapeutics eyes PRV with new FDA designation | ⇨ Geneva-based Amal Therapeutics has picked up about $10 million in Series B money for its work on peptide-based cancer vaccines. Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund invested alo... |
| 05.09.2017 | AMAL Therapeutics raises CHF 8.8 million in Series B round | |
| 05.09.2017 | AMAL Therapeutics raises CHF 8.8 million in first closing of Series B financing round | The Company will use the funds to progress its lead vaccine (ATP128) towards clinical studies and proof-of-concept in colorectal cancer. It will also further develop its proprietary therapeutic tumour vaccination technology platform called ... |
| 05.09.2017 | AMAL Therapeutics raises CHF 8.8 million in first closing of Series B financing round | AMAL Therapeutics raises CHF 8.8 million in first closing of Series B financing round 05.09.2017 11:00, Tsering Ngorkhangsar linkedIn facebook twitter instagram youtube -->
AMAL Therapeutics (AMAL), a venture leader and Venture Kick alum... |
| 14.09.2016 | Top 100 Swiss startups have been revealed | |
| 30.03.2016 | Amal Therapeutics raises CHF 3 million in a Series A financing round led by Boehringer Ingelheim Venture Fund | Amal Therapeutics is a Swiss biotech company developing and progressing therapeutic cancer vaccines. The company will use the funds to progress the preclinical development of its lead vaccine (ATP124) for colorectal cancer and to further de... |
| 30.03.2016 | Amal Therapeutics Raises CHF3M in Series A Funding | Amal Therapeutics, a Geneva, Switzerland-based biotech company, completed a CHF 3m (€2.75m) in Series A funding.
The round was led by Boehringer Ingelheim Venture Fund (BIVF) with participation from VI Partners and High-Tech Gründerfonds. I... |
| 30.03.2016 | Amal Therapeutics raises CHF 3 million in a Series A financing round | |
| 30.03.2016 | Daily funding roundup - March 30, 2016 | Zavante closed $45M Series A funding; MapD secured $10M; Invoca closed $30M Series D funding
Invoca, a marketing platform for call analytics and automation, closed a $30 million Series D round of funding led by Morgan Stanley Alternative In... |
| 30.03.2016 | Amal Therapeutics raises CHF 3 million in a Series A financing round led by Boehringer Ingelheim Venture Fund | Amal Therapeutics raises CHF 3 million in a Series A financing round led by Boehringer Ingelheim Venture Fund 30.03.2016 14:00, Lara Rossi linkedIn facebook twitter instagram youtube -->
(30.03.2016) Amal Therapeutics (Amal) completes CH... |
| 24.03.2016 | Amal Therapeutics receives CTI grant | |
| 06.11.2015 | 11 start-ups selected for Swiss Venture Day Romandie | |
| 15.09.2015 | Amal Therapeutics and Oslo University Hospital announce research collaboration | |
| 28.08.2015 | Start-ups selected for the 50th Swiss Venture Day | |
| 23.07.2015 | Amal Therapeutics publishes R&D findings in Cancer Research | The publication underlines the value of a novel immunotherapy class able to simultaneously inducing multi-epitopic immunity, T helper functions and immunologic memory. The article shows that vaccines tested are able to significantly prolong... |
| 23.07.2015 | Amal Therapeutics publishes R&D findings in Cancer Research | Amal Therapeutics publishes R&D findings in Cancer Research 23.07.2015 17:00, Lara Rossi linkedIn facebook twitter instagram youtube -->
TOP100 2014, 2012 venture leader USA and Venture Kick alumnus Amal Therapeutics recently announc... |
| 29.06.2015 | Amal achieves proof of concept | |
| 17.04.2015 | Nine hot start-ups, 400 visitors and Joe Jimenez | |
| 26.11.2014 | Four new CTI Start-up label companies | |
| 24.07.2014 | € 1.07 million grant to Amal Therapeutics and TransCure bioServices | |
| 09.07.2014 | Amal Therapeutics SA announces appointment of Johanna Holldack as Chairman | |
| 25.03.2014 | Amal Therapeutics, un exemple de recherche de Seed financing dans le domaine biotech | |
| 17.03.2014 | A rich pitching event in Western Switzerland at BioMed Up in Geneva | |
| 04.03.2014 | 10 companies selected for Life Sciences Start-up Day | |
| 21.02.2014 | Amal Therapeutics Raises Seed Funding | Amal Therapeutics SA, a Geneva, Switzerland and Berlin, Germany-based company focusing on the development of therapeutic cancer vaccines, raised a seed round of funding.
The round – whose amount was not disclosed – was led by Boehringer Ing... |
| 20.02.2014 | Amal Therapeutics SA raises seed round from Boehringer Ingelheim Venture Fund and High-Tech Gründerfonds | |
| 09.07.2013 | Volkswirtschaftsstiftung supports 3db Technologies, Amal Therapeutics and L.E.S.S. | |
| 24.03.2013 | 7 Regular and 2 Elevator Pitches at the Swiss Venture Day - 26.3.2013 -1400-1800 | |
| 15.03.2013 | Companies for next Swiss Venture Day selected | |
| - | Amal Therapeutics raises CHF 3 million in a Series A financing round led by Boehringer Ingelheim Venture Fund | Amal Therapeutics (Amal) completes CHF 3 million (EUR 2.75 million) Series A financing round with Boehringer Ingelheim Venture Fund (BIVF) as cornerstone investors. VI Partners and High-Tech Gründerfonds also participated in the round which... |
| - | Boehringer Ingelheim to acquire Swiss cancer vaccine developer for up to 325M euros | A large family-owned drugmaker in Germany plans to shell out more than $350 million to buy a cancer vaccine maker in Switzerland.
Ingelheim am Rhein, Germany-based Boehringer Ingelheim said Monday it would spend up to 325 million euros – or... |
| - | AMAL Therapeutics finalises €29 million (CHF 33.2 million) Series B round | |
| - | AMAL Therapeutics raises €8 million (CHF 8.8 million) in first closing of Series B financing round | - |
